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after ECMO, n = 35).  Results: CH screening results were aber-
rant in 67.3% (72/107) of the neonates screened during 
ECMO, in 73.1% (19/26) of the neonates screened before 
ECMO, and in 31.4% (11/35) of the neonates screened after 
ECMO (p < 0.001). Of the neonates with an aberrant screen-
ing result, all but 2 (i.e. 98%) had a low thyroxine concentra-
tion with a normal thyrotropin concentration at screening, 
as is seen in NTIS. None was diagnosed with CH. Mortality did 
not significantly differ between neonates with an aberrant 
screening result (32.4%) and neonates with a normal screen-
ing result (22.7%; p = 0.18). Screening before ECMO (OR 5.92; 
95% CI 1.93–18.20), screening during ECMO (OR 4.49; 95% CI 
1.98–10.19), and a higher Pediatric Logistic Organ Dysfunc-
tion-2 score (OR 1.31; 95% CI 1.04–1.66) were associated with 
an aberrant screening result.  Conclusions: Aberrant CH 
screening results were found in most ECMO-treated neo-
nates screened before or during ECMO, which is likely due to 
NTIS. Follow-up of thyroid hormone concentrations is best 
started after recovery from critical illness. Our results suggest 
that thyroxine therapy is not required during ECMO. 
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 Abstract 
 Background: Thyroid hormone concentrations may deviate 
from normal values during critical illness. This condition is 
known as nonthyroidal illness syndrome (NTIS), and it can 
influence the results of screening for congenital hypothy-
roidism (CH) during neonatal extracorporeal membrane ox-
ygenation (ECMO).  Objectives: To determine the incidence 
of aberrant CH screening results in ECMO-treated neonates, 
to identify possible determinants, and to follow up patients 
with abnormal thyroid hormone concentrations.  Methods: 
In this retrospective cohort study, we included 168 ECMO-
treated neonates admitted from 2004 to 2014 and screened 
by protocol and divided them into the following 3 groups: 
group 1 (screened during ECMO, n = 107), group 2 (screened 
shortly before ECMO, n = 26), and group 3 (screened shortly 
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 As thyroid hormones are essential for normal brain
development, children with congenital hypothyroidism 
(CH) are at risk for intellectual disability  [1] . CH screening 
and early treatment have almost eliminated intellectual 
disabilities caused by untreated CH. In the Netherlands, 
CH screening is primarily based on thyroxine (T4) screen-
ing with supplementary thyrotropin (TSH) and thyroxine-
binding globulin measurements aimed at identifying not 
only children with primary hypothyroidism but also chil-
dren with central hypothyroidism  [2] . However, interpre-
tation of the screening results can be complicated by fac-
tors that can transiently reduce thyroid hormone concen-
trations, such as prematurity  [3] , drug use  [4] , cardiac 
surgery  [5] , and critical illness  [6] . This condition of dis-
turbed thyroid hormone concentrations (low T4 and low 
triiodothyronine, increased reverse triiodothyronine, and 
normal or low TSH) during critical illness is referred to as 
nonthyroidal illness syndrome (NTIS) or euthyroid sick 
syndrome. It is important to distinguish between CH and 
NTIS because CH therapy should be initiated as soon as 
possible, whereas treatment for NTIS is not recommended 
 [6] . In previous studies critically ill neonates have had low-
er thyroid hormone concentrations than healthy neonates 
 [7–9] , and this has been associated with a prolonged hos-
pital stay and a higher mortality  [7, 9] . Low thyroid hor-
mone concentrations consistent with NTIS have been 
found in neonates on extracorporeal membrane oxygen-
ation (ECMO)  [10] . However, it is unknown whether 
ECMO exerts an influence on CH screening results and 
whether there are any implications of a positive CH screen-
ing result during ECMO. We therefore wanted to deter-
mine the incidence of aberrant CH screening results in 
ECMO-treated neonates, identify possible determinants 
of aberrant screening results, and follow up neonates with 
abnormal thyroid hormone concentrations.
 Materials and Methods 
 Patients 
 In this retrospective cohort study, we included ECMO-treated 
neonates admitted between January 1, 2004, and December 31, 
2014, who underwent CH screening in either of the two pediatric 
ECMO centers in the Netherlands [i.e. Erasmus MC-Sophia Chil-
dren’s Hospital (Rotterdam) and Radboud UMC-Amalia Chil-
dren’s Hospital (Nijmegen)]. These centers use the same entry cri-
teria and treatment protocols, but the prime fluid is different: eryth-
rocyte concentrate is used in the Erasmus MC-Sophia Children’s 
Hospital, and erythrocyte concentrate with fresh frozen plasma 
(FFP) is used in the Radboud UMC-Amalia Children’s Hospital. 
ECMO was initiated in case of reversible severe respiratory failure 
with an estimated mortality risk >80% as described by Stolar et al. 
 [11]. The exclusion criteria were: screening not in conformity with 
the Dutch neonatal screening protocol, incomplete or no screening 
results available, no registration in the Dutch civil registry (not in-
vited for screening), and ECMO initiated after 8 days of life (not 
critically ill at the scheduled time of screening). We created the fol-
lowing 3 groups: group 1 (screened during ECMO), group 2 
(screened shortly before ECMO), and group 3 (screened shortly 
after ECMO). Neonates in groups 2 and 3 were considered criti-
cally ill at screening, but they did not receive ECMO at that time. 
CH screening results were obtained from the National Institute for 
Public Health and Environment (RIVM). In the Netherlands, CH 
screening is primarily based on T4 measurements by immuno-
chemical blood spots sampled 72–168 h after birth. The method is 
described in detail in the supplementary material (for all online 
suppl. material, see www.karger.com/doi/10.1159/000448238). We 
classified the initial screening results as either normal or aberrant 
(abnormal or borderline result on the first heel puncture). In neo-
nates with an aberrant result, the pattern of changes in thyroid hor-
mone concentrations was classified into 3 categories: abnormally 
low T4 [ ≤ –3.0 SD score (SDS)] with normal TSH ( ≤ 7 mU/l), mild-
ly lowered T4 (–3.0 < T4  ≤ –1.6 SDS) with normal TSH ( ≤ 7 mU/l), 
and mildly lowered T4 (–3.0 < T4  ≤ –1.6 SDS) with mildly elevated 
TSH (7 < TSH  ≤ 21 mU/l). Relevant clinical data were collected. 
The primary diagnosis was defined as the underlying diagnosis re-
quiring ECMO support. Illness severity was estimated using the 
Pediatric Risk of Mortality III (PRISM III) score  [12] , calculated for 
the first 24 h of Pediatric Intensive Care Unit (PICU) stay, and the 
Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score  [13] , 
computed for the 24 h prior to the first heel puncture. Povidone-
iodine and radiocontrast materials were not used. Ethical approval 
was obtained from the local ethics committees (CMO 2005/253).  
 Follow-Up of Neonates with Abnormal Thyroid Hormone 
Concentrations 
 Follow-up serum free T4 (FT4) and TSH concentrations were 
obtained from the medical charts of neonates with an abnormal 
CH screening result. FT4 and TSH were compared to the reference 
values established by Lem et al.  [14] . An abnormal value was de-
fined as <–2 SDS or >+2 SDS compared to the reference values.
 Data Analysis 
 Data are expressed as means ± SD, medians (IQR), or numbers 
(%), as appropriate. Categorical variables were compared using the 
χ 2 test or Fisher’s exact test. Student’s t test or a one-way ANOVA 
was used for normally distributed variables, and the Mann-Whit-
ney U test or the Kruskal-Wallis test was applied for non-normally 
distributed variables. To correct for multiple testing, the Bonfer-
roni correction was used, and adjusted p values are given. Univari-
ate logistic regression analyses served to identify associations be-
tween clinical variables [primary diagnosis, time of screening (be-
fore/during/after ECMO), PRISM III score, PELOD-2 score, and 
drug usage] and aberrant screening results. Use of the following 
intravenous drugs  ≤ 8 h prior to screening was recorded: dopamine, 
dobutamine, furosemide, morphine, fentanyl, and hydrocortisone. 
From a few hours after administration, these drugs can temporar-
ily affect thyroid hormone concentrations; pretreatment levels are 
reached within hours after discontinuation of the drug  [4, 15–19] . 
Variables with p  ≤ 0.20 were included in the multiple logistic re-
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gression analysis. Multicollinearity was not found. Data were ana-
lyzed using SPSS 21.0 for Windows (IBM Corporation, Armonk, 
N.Y., USA). Statistical significance was accepted at the 5% level.
 Results 
 Patients 
 ECMO was initiated in 318 neonates ( fig. 1 ). We in-
cluded 168 neonates divided into 3 groups.  Table  1 
shows the patient characteristics. In group 3, ECMO was 
started later, and CH screening was performed later. 
Further, the duration of ECMO therapy was shorter in 
group 3. The median PELOD-2 score was higher in 
group 1 than in group 3 (adjusted p = 0.045). Eight pa-
tients received levothyroxine therapy (online suppl. ta-
ble 2). Three of them had a normal initial screening re-
sult and developed hypothyroxinemia later, which was 
identified by routine laboratory tests. One patient was 
diagnosed with thyroid dyshormonogenesis and re-





n = 26 
Group 3
(screened after ECMO):
n = 35 
Group 1
(screened during ECMO):
n = 107 
Exclusion
Screening not in conformity
with the protocol1: n = 83
Deceased prior to screening: n = 27
No/incomplete data: n = 8
No Dutch civil registration: n = 2
ECMO initiated after 8 days of
life: n = 30








Gestational age, weeks 39.9 (38.1 – 41.0) 40.0 (37.0 – 41.0) 40.4 (39.0 – 41.1) 0.21
Birth weight, g 3,247 ± 631 3,256 ± 704 3,541 ± 595 0.06
Male sex 62 (57.9) 17 (65.4) 20 (57.1) 0.77
Primary diagnosis 0.08
Meconium aspiration syndrome 41 (38.3) 9 (34.6) 17 (48.6)
Congenital diaphragmatic hernia 35 (32.7) 6 (23.1) 5 (14.3)
Sepsis 11 (10.3) 3 (11.5) 5 (14.3)
Persistent pulmonary hypertension 10 (9.3) 6 (23.1) 8 (22.9)
Other1 10 (9.3) 2 (7.7) 0 (0)
Age at the start of ECMO therapy, days of life 1 (0 – 2) 6 (5 – 7) 1 (0 – 1) <0.001
Duration of ECMO therapy, days 7 (5 – 9) 6 (4 – 7) 3 (2 – 4) <0.001
PRISM III score (first 24 h of PICU admission) 17 (15 – 23) 17 (9 – 21) 17 (12 – 21) 0.12
Age at CH screening, days of life 4 (4 – 5) 4 (4 – 4) 6 (5 – 7) <0.001
PELOD-2 score (24 h prior to CH screening) 6 (6 – 7) 5 (5 – 7) 6 (5 – 7) 0.03
 Data are expressed as means ± SD, medians (IQR), or numbers (%). 1 Congenital heart disease, congenital cystic adenomatoid mal-
formation, recurrent pneumothoraces, infant respiratory distress syndrome in combination with pneumothorax, meconium peritonitis, 
respiratory failure of unknown cause.
 Fig. 1. Flowchart of the study population. 
 1  Screening performed too early (n = 1) or 
too late (n = 82). 
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 CH Screening Results  
 Table 2 shows the screening results. The incidence of 
aberrant results was higher in group 1 (67.3%) and group 
2 (73.1%) than in group 3 (31.4%; both adjusted p < 
0.001). At the initial screening, the combination of low T4 
and normal TSH was found in 100 of 102 neonates ( ta-
ble 2 ). Neonates with an aberrant screening result were 
treated longer with ECMO and had higher PELOD-2 
scores than those with a normal screening result (online 
suppl. table 3). The incidence of aberrant screening re-
sults in group 1 in both centers was similar and thus ir-
respective of the use of FFP in the prime fluid (67.2% with 








Normal result → no further action







Abnormally low T4, normal TSH2 42 10 5
Dubious result → second screening 30 (28.0) 9 (34.6) 6 (17.1)
Mildly lowered T4, normal TSH3 28 9 6
Mildly lowered T4, mildly elevated TSH4 2 – –
Second screening
Died before the second screening 1 0 0
Normal result → no further action 22 9 6
Abnormal result → referral1 7 0 0
Abnormally low T4, normal TSH2 1 – –
Mildly lowered T4, normal TSH3 2 – –
Mildly lowered T4, mildly elevated TSH4 4 – –
 1 To a pediatrician for further analysis. 2 T4 ≤–3.0 SDS and TSH ≤7 mU/l. 3 –3.0 < T4 ≤ –1.6 SDS and TSH ≤7 mU/l. 4 –3.0 < T4 ≤ 
–1.6 SDS and 7 < TSH ≤ 21 mU/l.
Group 1 (screened during ECMO)










Normal FT4 with high TSH: n = 6
Low FT4 with high TSH: n = 1
Low FT4 with normal TSH: n = 2
Group 2 (screened before ECMO)





Group 3 (screened after ECMO)






Normal FT4 with high TSH:
n = 1
 Fig. 2. Follow-up of neonates with abnormal screening results.  1  Deceased before follow-up of thyroid hormone 
concentrations was performed.  2  Transferred to another hospital. 
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FFP vs. 67.3% without FFP; p = 1.00). The proportion of 
aberrant screening results in group 1 was not dependent 
on the time elapsed between the start of ECMO and blood 
sampling for CH screening (data not shown).
 Follow-Up of Neonates with Abnormal Thyroid 
Hormone Concentrations 
 The follow-up results are shown in  figure 2 . Sixteen 
neonates died before the follow-up was initiated, and 1 
was transferred to another hospital. Thyroid hormone 
concentrations normalized in 37 neonates at the median 
age of 10 days (IQR 8–17.5). In 29 of those neonates, this 
happened before 28 days of life; thyroid hormone con-
centrations normalized in the other 8 neonates between 
30 and 108 days of life. Normalization of thyroid hor-
mone concentrations could not be confirmed in 10 chil-
dren ( fig. 2 ). At the last follow-up, low FT4 values ranged 
from 12.0 to 12.7 pmol/l and high TSH values ranged 
from 5.7 to 14.9 mU/l in these children.
 Aberrant CH Screening Results and Mortality 
 The mortality rate before hospital discharge was 28.6% 
(48/168). The mortality rate was not significantly higher 
in children with an aberrant CH screening result (32.4%) 
than in children with a normal screening result (22.7%;
p = 0.18). 
 Associations between Clinical Variables and an 
Aberrant CH Screening Result 
 In the univariate logistic regression analyses, screening 
before ECMO, screening during ECMO, and a higher 
PELOD-2 score were significantly associated with an ab-
errant screening result ( table 3 ). In the multivariate mod-
el, screening before and during ECMO remained associ-
ated with an aberrant screening result. 
 Discussion 
 More than two thirds of the initial CH screening re-
sults were aberrant in ECMO-treated neonates screened 
before and during ECMO. Low T4 in combination with a 
normal TSH concentration was found in all but 2 neo-
nates with an aberrant screening result, which normal-
ized rapidly without treatment in most cases. None of 
these children was diagnosed with CH. This suggests that 
aberrant screening results are due to NTIS, and that levo-
thyroxine therapy during ECMO is not required. The in-
cidence of aberrant screening results in the group of neo-
nates screened after ECMO was significantly lower than 
that in the 2 other groups, possibly reflecting that clinical 
recovery occurs during ECMO.
 Reduced thyroid hormone concentrations have been 
found in critically ill term neonates treated with or with-
out ECMO  [7–10] . The effect of neonatal ECMO on thy-
 Table 3.  Results of logistic regression analyses: clinical variables associated with an aberrant screening result
Univariate model p value Multivariate model1 p value
Time of screening
After ECMO (ref.) 1.00 – 1.00 –
Before ECMO 5.92 (1.93 – 18.20) 0.002 4.59 (1.11 – 18.93) 0.04
During ECMO 4.49 (1.98 – 10.19) <0.001 3.19 (1.22 – 8.32) 0.02
PELOD-2 score 1.31 (1.04 – 1.66) 0.02 1.27 (0.99 – 1.63) 0.06
Primary diagnosis
Meconium aspiration syndrome (ref.) 1.00 – 1.00 –
Congenital diaphragmatic hernia 1.78 (0.82 – 3.89) 0.15 1.41 (0.60 – 3.34) 0.44
Others 1.51 (0.73 – 3.13) 0.27 1.34 (0.56 – 3.16) 0.51
Dopamine
No (ref.) 1.00 – 1.00 –
Yes 1.63 (0.84 – 3.18) 0.15 1.01 (0.46 – 2.21) 0.98
Morphine
No (ref.) 1.00 – 1.00 –
Yes 1.98 (0.75 – 5.19) 0.17 1.60 (0.54 – 4.73) 0.40
 Values are presented as OR (95% CI). ref. = Reference. 1 Adjusted OR, adjusted for all other variables shown in the table.
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roid hormone concentrations has been studied only by 
Stewart et al.  [10] . They found a decline in all thyroid 
hormone concentrations directly after the start of ECMO 
in a cohort of 14 neonates, which suggests a dilutional ef-
fect. Additionally, Agus and Jaksic  [20] reported that thy-
roid hormone concentrations in ECMO prime fluid were 
significantly below normal. They suggested that these 
concentrations would be even lower in prime fluid with-
out FFP  [20] . However, in the present study the incidence 
of aberrant screening results was not higher in the center 
without FFP in the prime fluid. Although we acknowl-
edge that the occurrence of hemodilution after ECMO 
cannulation plays a role in the lowering of thyroid hor-
mone concentrations, we think that NTIS contributes 
more to this, and that hemodilution may further lower 
thyroid hormone concentrations in critically ill neonates. 
This assumption is supported by our finding that the in-
cidences of aberrant screening results did not significant-
ly differ between screening before (73.1%) and during 
(67.3%) ECMO. 
 Screening before and during ECMO and a higher 
PELOD-2 score were associated with an aberrant screen-
ing result. Further, neonates with an aberrant screening 
result had higher PELOD-2 scores than neonates with a 
normal screening result, suggesting an influence of illness 
severity. Nevertheless, the use of the PELOD-2 score has 
some limitations. Though validated for a broad group of 
PICU patients  [13] , its performance in ECMO-treated 
neonates is unknown. Further, the PELOD-2 score is af-
fected by treatment. Therefore, we cannot firmly con-
clude that illness severity plays a role in causing aberrant 
screening results.
 Dopamine has been found to suppress TSH in previ-
ous studies  [17, 19] , but we did not find an association 
between dopamine and an aberrant screening result. 
Therefore, dopamine does not seem to be the main cause 
of aberrant CH screening results. However, our study 
does not allow pinpointing of the exact effect of dopa-
mine on thyroid hormone concentrations.
 Now, clinicians will be most concerned with the impli-
cations of aberrant CH screening results. As we found a 
lower risk of aberrant screening results in neonates 
screened after ECMO, follow-up of thyroid hormone con-
centrations should be started after ECMO and ideally after 
recovery from critical illness. However, because T4 treat-
ment should not be started later than the first 2 weeks of 
life to prevent intellectual disabilities  [21] , we recommend 
that thyroid function tests be repeated before this age. 
 The consequences of low thyroid hormone concentra-
tions during critical illness remain controversial. Correla-
tions between low thyroid hormone concentrations and 
adverse outcomes have been found, including increased 
mortality  [8, 9, 22] . We did not find a significant differ-
ence in mortality rates between neonates with an aberrant 
screening result and neonates with a normal screening 
result. However, it should be noted that our sample size 
was small, and the results could have been biased by the 
lack of screening results for the 27 neonates who died be-
fore screening was performed. 
 As thyroid hormones are essential for early brain de-
velopment, transiently reduced thyroid hormone con-
centrations during early life could affect neurodevelop-
ment, which has been shown in premature infants  [23, 
24] . In that case, supplementation of thyroid hormones 
during NTIS could be beneficial. On the other hand, a re-
cent study in young adults did not confirm this associa-
tion between transient hypothyroxinemia of prematurity 
and adverse neurodevelopmental outcomes  [25] . Fur-
thermore, neonatal T4 supplementation was not benefi-
cial in premature infants  [26] . As levothyroxine therapy 
has not been proven to be beneficial, and thyroid hor-
mone concentrations normalized rapidly in most cases, 
we do not advise starting levothyroxine therapy in EC-
MO-treated neonates based on an aberrant screening re-
sult in the first 2 weeks of life.
 To our knowledge, this is the first study reporting on 
CH screening results in ECMO-treated neonates with fol-
low-up of thyroid function. A strength is the use of an ef-
ficient CH screening method. Further, this is the largest 
cohort study investigating CH screening results in EC-
MO-treated neonates. Limitations are its retrospective 
design, its small sample size, and the lack of a strict sched-
ule to follow up abnormal thyroid hormone concentra-
tions. The small sample size does not allow drawing of a 
strong conclusion about the influence of the time of sam-
pling during ECMO on screening results. Further, the ex-
act date of normalization in some patients with abnormal 
thyroid hormone levels remains uncertain.
 In conclusion, we found a higher incidence of aberrant 
CH screening results in neonates screened before (73.1%) 
or during (67.3%) ECMO than in neonates screened after 
(31.4%) ECMO. All but 2 neonates (i.e. 98%) with an ab-
errant screening result had low T4 concentrations with 
normal TSH, as is seen in NTIS. Thyroid hormone con-
centrations normalized rapidly in most, and none of these 
children was diagnosed with CH. Our results suggest that 
T4 therapy is not required during ECMO. Follow-up of 
abnormal thyroid hormone concentrations is best per-
formed after recovery from critical illness.
 Thyroid Screening during Neonatal 
ECMO 
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